Infections caused by Enterobacterales have become more difficult to treat due to increasing antibiotic resistance, in particular, in the case of production of carbapenemases. Bacterial peritonitis is a common complication of peritoneal dialysis, being Citrobacter spp., an uncommon cause of this syndrome. We report the first case of bacterial peritonitis in continuous ambulatory peritoneal dialysis (CAPD) caused by Citrobacter werkmanii resistant to all beta-lactams, gentamicin, and cotrimoxazole, and also the new anti-gram-negative molecules ceftazidime/avibactam and ceftolozane/tazobactam. The molecular analysis of the strain demonstrated the presence of blaVIM metallo-β-lactamase gene. The patient was effectively cured with a course of systemic tigecycline, colistin, and meropenem.
Introduction
Bacterial peritonitis is a common complication of continuous ambulatory peritoneal dialysis (CAPD), with mortality rate ranging from 1 to 6% [1] . This condition is usually caused by gram-positive organisms (67%), most commonly Staphylococcus epidermidis [2] . However, during the last years, their incidence as causative agents has been steadily decreasing, possibly because of improved care of the catheter exit-site [3] . Other possible etiologies of peritonitis in CAPD are gram-negative organisms (28%), fungi and anaerobic germs (each 2.5%), even if up to 20% of secondary peritonitis are culture-negative.
Citrobacter spp. is an unusual pathogen causing this syndrome, but it is correlated with a less favorable profile in terms of antimicrobial susceptibility and with a higher mortality, reaching up to 18% [4] . Among Citrobacter spp., the most common species represented as a cause of CAPD-associated peritonitis is Citrobacter freundii.
We report here what is, to our knowledge, the first reported case of CAPD-associated bacterial peritonitis caused by multidrug resistant Citrobacter werkmanii.
Case Report
We report the case of a 42-year-old man with end-stage renal disease (ESRD) caused by a nephropathy of unknown origin, undergoing CAPD while on waiting list for kidney transplant. In March 2018, during pre-transplant exams, pathological diffuse lymphadenopathy was noted at computed tomography (CT) scans, and after histological finding of non-necrotizing granulomatous disease, he was diagnosed with lymph nodal sarcoidosis. Thus, therapy with corticosteroids was started at the dose of 1 mg/kg/day of prednisone. After 2 months of steroid treatment, in May 2018, he was admitted to the Pneumology Department of our hospital for acute onset of fever and respiratory failure. CT scan demonstrated the presence of hydro-pneumothorax and bilateral tree-in-bud pattern. To better define the cause of respiratory distress, he underwent diagnostic bronchoalveolar lavage (BAL) with finding of a positive molecular test for Pneumocystis jiroveci DNA (RealCycler Pneumocystis jiroveci, Progenie Molecular, ES) and for Mycobacterium tuberculosis hominis DNA (GeneXpert MTB/RIF assay, Cepheid, Sunnyvale, CA). Additionally, concomitant serum beta-D-glucan proved to be out of range. Thus, after receiving a diagnosis of Pneumocystis jiroveci pneumonia (PJP) and pulmonary tuberculosis, he was transferred to our infectious diseases unit, and appropriate treatments for these infections were started (trimethoprim-sulfamethoxazole and isoniazid + rifampin + ethambutol + pyrazinamide, respectively), with clinical improvement. We also performed serological HIV test that resulted negative.
One month after admission, the hospitalization was complicated with sudden onset of septic shock and intense abdominal pain with positive Blumberg sign and diffuse peritonism. A sample of peritoneal fluid was collected in order to rule out CAPD-associated peritonitis, and based on our center protocols, empirical antibiotic treatment with parenteral ceftazidime + vancomycin was started. Blood cultures were performed at the onset of septic shock before initiation of antibiotic therapy, which resulted negative. Screening rectal swabs to detect carbapenem-resistant Enterobacterales resulted negative throughout the hospital stay.
The analysis of the peritoneal fluid collected from the peritoneal dialysis catheter showed the presence of 7.98 × 10 9 /L leukocytes with a predominance of neutrophils (7.20 × 10 9 /L), and the culture resulted positive for a strain of C. werkmanii resistant to not only all beta-lactams (including carbapenems), gentamicin, and cotrimoxazole, but also the new anti-gramnegative molecules ceftazidime/avibactam and ceftolozane/ tazobactam. After the availability of the susceptibility report, target antibiotic therapy with high-dose meropenem (1000 mg/day), tigecycline (100 mg loading dose, then 50 mg twice a day), and colistimethate (9 MU loading dose, then 2 MU/ day) was administered. For our patient, this was the fourth episode of bacterial peritonitis correlated to peritoneal dialysis. Therefore, in accordance with nephrologists, the peritoneal catheter was removed and the patient switched to hemodialysis, performed through a temporary dialysis central venous catheter. After switching to intermittent hemodialysis, the dose of colistimethate was increased to 2 MU on nondialysis days and 3 MU after dialysis. The total duration of antibiotic therapy was of 14 days.
After the first week of treatment, the analysis of peritoneal fluid showed a significant decrease in leukocyte count (0.50 × 10 9 /L with 0.20 × 10 9 /L neutrophils). The follow-up culture of peritoneal fluid performed at the end of antibiotic therapy resulted negative.
There was also a progressive improvement of clinical conditions, resolution of fever, and normalization of serum inflammatory markers.
Routine identification and antimicrobial susceptibility testing of C. werkmanii strain were carried out using the Vitek-2 automated system (BioMérieux, Marcy-L'etoile, France) and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [5] . Complete antibacterial susceptibility and minimum inhibiting concentrations (MICs) of the strain isolated are shown in Table 1 . To note, although latest evidence suggests that colistin susceptibility should be confirmed with broth microdilution [6] , this procedure is not routinary at our institute, and it was not carried out in the case reported.
Given the multi-drug resistant (MDR) profile, further tests were carried out: a synergy test using imipenem and EDTA disks was used to detect metallo-β-lactamase (MBL) production [7] , and polymerase chain reaction (PCR) amplification of blaVIM, blaIMP, and blaNDM genes was performed [8] and revealed the presence of blaVIM gene (Fig. 1) . The patient was discharged after 93 days of in-hospital care with anti-tubercular therapy and secondary prophylaxis for PJP. After multidisciplinary re-evaluation of the case, interruption of steroid therapy with gradual tapering was decided. The patient was regularly evaluated at our outpatient clinic for the whole duration of anti-tubercular treatment (12 months), and no complications occurred. With regards to the MDR infection, it was successfully cleared despite the use of suboptimal, salvage therapy, and to date, the patient is in good health and recently underwent kidney transplant.
Discussion
Citrobacter spp. infections can usually be effectively treated with beta-lactam antibiotics, even if the choice of empiric regimens depends on several parameters, such as local resistance pattern (e.g., prevalence of AmpC beta-lactamases), fragility of the patient, and severity of the infection [9] .
Reports of Citrobacter spp. harboring metallo-β-lactamases (MBLs) have been described before, but their isolation from significant clinical specimens remains a rare event in Europe. Recent microbiological evidence has shown the emergence of New Delhi metallo-β-lactamase (blaNDM)-producing C. werkmanii in India [10] . Another microbiological report has described the presence of MDR C. werkmanii harboring a novel blaVIM-48 resistance gene in rectal swabs [11] .
To our knowledge, the case described in this report is the first clinically significant case of bacterial peritonitis caused by MBL-producing C. werkmanii, resistant to all betalactams, gentamicin, and cotrimoxazole, and also ceftazidime/avibactam and ceftolozane/tazobactam.
Given the intra-abdominal nature of the infection and the negativity of blood cultures, we chose to privilege an antimicrobial regimen based on tigecycline associated with colistin. This latter drug in recent years has played an important role as salvage therapy for otherwise untreatable gram-negative infections, most notably those caused by MDR and extensively drug resistant (XDR) strains of Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacterales [12] . Although questionable on the basis of susceptibility testing, high-dose meropenem was added to the treatment because of clinical severity of infection, based on our experience about the use of high-dose carbapenems for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing organisms [13, 14] . Upon treatment initiation, no precise MIC determination for carbapenems of the strain isolated was available, as well as the precise resistance mechanism (MBL vs KPC).
Fortunately, timely diagnosis, prompt institution of effective antimicrobial therapy, and catheter removal resulted in a favorable outcome. The patient recently underwent kidney transplant without complications.
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